6 / 38
Balar, Lancet Oncol 2017
374 patients
Response rate 24% (89). CR 5% (17)
Median duration of response: not reached
19 (5%) patients discontinued for treatment-related adverse events
One treatment related death (myositis)
|
|
6 / 38
6 / 38
Balar, Lancet Oncol 2017
374 patients
Response rate 24% (89). CR 5% (17)
Median duration of response: not reached
19 (5%) patients discontinued for treatment-related adverse events
One treatment related death (myositis)